Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Financing Activities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash from Financing Activities for 16 consecutive years, with -$403.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to -$403.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $425.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $524.5 million for FY2025, 43.64% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$403.8 million at Cytokinetics, down from $4.8 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $821.0 million in Q2 2024, with the low at -$403.8 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $93.3 million, with a median of $19.5 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities crashed 32590.91% in 2021, then skyrocketed 14895.63% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $19.5 million in 2021, then surged by 53.21% to $29.9 million in 2022, then surged by 464.83% to $168.8 million in 2023, then crashed by 97.97% to $3.4 million in 2024, then tumbled by 11888.88% to -$403.8 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$403.8 million, $4.8 million, and $3.4 million for Q4 2025, Q1 2025, and Q3 2024 respectively.